{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:02Z","timestamp":1793978822708,"version":"4.8.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.pharmthera.2026.109133","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:06:09Z","timestamp":1792623969000},"page":"109133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Navigating the landscape of stem cell therapeutics: Overcoming translational hurdles via emerging technologies and regulatory frontiers"],"prefix":"10.1016","volume":"289","author":[{"given":"Se-Young","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Shin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Hyune","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Chul","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jamaoncol.2015.5137","article-title":"Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada","volume":"2","author":"Acuna","year":"2016","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.engreg.2025.07.004","article-title":"Current advances and prospects in biomaterials-guided tools for liver organoids research","volume":"6","author":"Ahmed","year":"2025","journal-title":"Engineered Regeneration"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109133_bb0015","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s13770-026-00810-8","article-title":"Harnessing Artificial Intelligence for Regeneration of Endometrium in Asherman\u2019s Syndrome","volume":"23","author":"Anbalagan","year":"2026","journal-title":"Tissue Engineering and Regenerative Medicine"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0020","series-title":"Astellas Receives Advanced Manufacturing Technology Designation by U.S. FDA for Maholo Robotic Cell Culture Automation System","author":"Astellas","year":"2025"},{"issue":"10044","key":"10.1016\/j.pharmthera.2026.109133_bb0025","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","article-title":"Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: A multicentre single-group phase 2 trial","volume":"388","author":"Atkins","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0030","series-title":"Maestro MEA Platform Powers First Stem Cell Cardiac Safety Assay in FDA ISTAND Program","author":"Axion Biosystems","year":"2026"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.stem.2017.09.014","article-title":"Human trials of stem cell-derived dopamine neurons for Parkinson\u2019s disease: Dawn of a New Era","volume":"21","author":"Barker","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"10033","key":"10.1016\/j.pharmthera.2026.109133_bb0040","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(15)00516-4","article-title":"The World report on ageing and health: A policy framework for healthy ageing","volume":"387","author":"Beard","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"4866","key":"10.1016\/j.pharmthera.2026.109133_bb0045","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/197452a0","article-title":"Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells","volume":"197","author":"Becker","year":"1963","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/toxsci\/kfad124","article-title":"Enabling novel paradigms: A biological questions-based approach to human chemical hazard and drug safety assessment","volume":"198","author":"Berridge","year":"2024","journal-title":"Toxicological Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109133_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166712","article-title":"Stem cells in the treatment of Alzheimer\u2019s disease \u2013 Promises and pitfalls","volume":"1869","author":"Bhatti","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109133_bb0060","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s13770-025-00748-3","article-title":"Human nasal olfactory stem cell-derived extracellular vesicles improve the repair of rat nerves","volume":"22","author":"Bonnet","year":"2025","journal-title":"Tissue Engineering and Regenerative Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109133_bb0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1574888X12666170915120620","article-title":"A systematic review and meta-analysis of clinical trials of mesenchymal stem cell therapy for cartilage repair","volume":"13","author":"Borakati","year":"2018","journal-title":"Current Stem Cell Research & Therapy"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109133_bb0070","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.stem.2023.09.014","article-title":"Decoding aging-dependent regenerative decline across tissues at single-cell resolution","volume":"30","author":"Cai","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13287-025-04252-2","article-title":"Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Cao","year":"2025","journal-title":"Stem Cell Research & Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0080","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jor.1100090504","article-title":"Mesenchymal stem cells","volume":"9","author":"Caplan","year":"1991","journal-title":"Journal of Orthopaedic Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109133_bb0085","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/sctm.17-0051","article-title":"Mesenchymal stem cells: Time to change the name!","volume":"6","author":"Caplan","year":"2017","journal-title":"Stem Cells Translational Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): Molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1400347","article-title":"The issue of heterogeneity of MSC-based advanced therapy medicinal products\u2013a review","volume":"12","author":"\u010cesnik","year":"2024","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0100","unstructured":"CGT Catapult. (2024). Annual Review 2024\u2014Cell and Gene Therapy. https:\/\/ct.catapult.org.uk\/about\/annual-review\/annual-review-2024."},{"issue":"436","key":"10.1016\/j.pharmthera.2026.109133_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap9630","article-title":"Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies","volume":"10","author":"Chabannon","year":"2018","journal-title":"Science Translational Medicine"},{"issue":"25","key":"10.1016\/j.pharmthera.2026.109133_bb0110","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1016\/j.cell.2025.09.010","article-title":"Phase 1\/2a clinical trial of hESC-derived dopamine progenitors in Parkinson\u2019s disease","volume":"188","author":"Chang","year":"2025","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0115","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s13770-025-00719-8","article-title":"Recent advances in three-dimensional in vitro models for studies of liver fibrosis","volume":"22","author":"Chi","year":"2025","journal-title":"Tissue Engineering and Regenerative Medicine"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0120","series-title":"Cell and gene therapy industry and regulatory trends (2023-2025) (BioIN regulation No. 2025\u20135)","first-page":"1","author":"Choi","year":"2025"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121156","article-title":"Tonsil-derived mesenchymal stem cells incorporated in reactive oxygen species-releasing hydrogel promote bone formation by increasing the translocation of cell surface GRP78","volume":"278","author":"Choi","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.omtm.2019.12.010","article-title":"CRISPR-Cpf1 activation of endogenous BMP4 gene for osteogenic differentiation of umbilical-cord-derived mesenchymal stem cells","volume":"17","author":"Choi","year":"2020","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0135","series-title":"World\u2019s First iPSC-Derived Cardiomyocyte Therapy for Heart Failure Receives Conditional Approval in Japan","author":"Cuorips Inc","year":"2026"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0140","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.4114","article-title":"Phase 1 clinical study of an embryonic stem cell\u2013derived retinal pigment epithelium patch in age-related macular degeneration","volume":"36","author":"Da Cruz","year":"2018","journal-title":"Nature Biotechnology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/rej.2009.0872","article-title":"Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells","volume":"12","author":"Dash","year":"2009","journal-title":"Rejuvenation Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/wound.2021.0123","article-title":"Cryopreserved placental membrane allograft reduces the likelihood of developing a new or recurring foot ulcer and all-cause mortality in diabetic patients when compared with other cellular- and tissue-based products","volume":"12","author":"DaVanzo","year":"2023","journal-title":"Advances in Wound Care"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0155","article-title":"Industrialization of 3D hiPSC-cardiac microtissues for high-throughput cardiac safety and drug discovery screening","author":"De Korte","year":"2025","journal-title":"Trends in Biotechnology"},{"issue":"372","key":"10.1016\/j.pharmthera.2026.109133_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3480","article-title":"CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease","volume":"9","author":"De Ravin","year":"2017","journal-title":"Science Translational Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109133_bb0165","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jcyt.2025.05.003","article-title":"Artificial intelligence, machine learning, and digitalization systems in the cell and gene therapy sector: A guidance document from the ISCT industry committees","volume":"27","author":"Di Cerbo","year":"2025","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.stem.2008.09.002","article-title":"Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals","volume":"3","author":"Eiraku","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0180","author":"European Parliament and the Council of the European Union"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0185","unstructured":"Faus, J., & Gonzalo, C. (2025). The hospital exemption pathway for non-industrially manufactured advanced therapy medicinal products: A fragmented landscape in the face of EU legislative reform. https:\/\/www.ibanet.org\/hospital-exemption-pathway-advanced-therapy."},{"key":"10.1016\/j.pharmthera.2026.109133_bb0190","series-title":"Expedited Programs for Regenerative Medicine Therapies for Serious Conditions","author":"FDA","year":"2025"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0195","series-title":"Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use","author":"FDA","year":"2020"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0200","series-title":"Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry","author":"FDA","year":"2024"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0205","series-title":"Innovative Science and Technology Approaches for New Drugs (ISTAND) Program","author":"FDA","year":"2025"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0210","series-title":"FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation","author":"FDA","year":"2026"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0215","author":"Ferdman"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109133_bb0220","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","article-title":"Genotoxic effects of base and prime editing in human hematopoietic stem cells","volume":"42","author":"Fiumara","year":"2024","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tmrv.2015.11.004","article-title":"Unraveling the mesenchymal stromal cells\u2019 paracrine immunomodulatory effects","volume":"30","author":"Fontaine","year":"2016","journal-title":"Transfusion Medicine Reviews"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109133_bb0230","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0235","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00007890-197404000-00001","article-title":"Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues: cloning in vitro and retransplantation in vivo","volume":"17","author":"Friedenstein","year":"1974","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109133_bb0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00007890-197108000-00001","article-title":"Osteogenic precursor cells of bone marrow in radiation chimeras","volume":"12","author":"Friedenstein","year":"1971","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0245","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.bbmt.2020.02.023","article-title":"Mesenchymal stromal cells for graft-versus-host disease: a trilogy","volume":"26","author":"Galipeau","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109133_bb0250","doi-asserted-by":"crossref","first-page":"2500301","DOI":"10.1002\/adhm.202500301","article-title":"Organoid vascularization: strategies and applications","volume":"14","author":"Gao","year":"2025","journal-title":"Advanced Healthcare Materials"},{"issue":"10258","key":"10.1016\/j.pharmthera.2026.109133_bb0255","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"7630","key":"10.1016\/j.pharmthera.2026.109133_bb0260","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nature20168","article-title":"Designer matrices for intestinal stem cell and organoid culture","volume":"539","author":"Gjorevski","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109133_bb0265","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109133_bb0270","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nature Biotechnology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109133_bb0275","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"One million haemopoietic stem-cell transplants: A retrospective observational study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"The Lancet Haematology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0280","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/cpt.3117","article-title":"Measurement and mitigation of bias in artificial intelligence: a narrative literature review for regulatory science","volume":"115","author":"Gray","year":"2024","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109133_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045532","article-title":"Standardization of the teratoma assay for analysis of pluripotency of human ES cells and biosafety of their differentiated progeny","volume":"7","author":"Gropp","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0290","series-title":"Cellino\u2019s iPSC Manufacturing Technology Receives FDA Advanced Manufacturing Technology (AMT) Designation","author":"Ha","year":"2025"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2025.107902","article-title":"Design and synthesis of gold nanoparticle-loaded hydrogel for stem cell delivery to promote cardiac cell regeneration after myocardial infarction","volume":"116","author":"Habibi","year":"2026","journal-title":"Journal of Drug Delivery Science and Technology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109133_bb0300","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3390\/cells10081959","article-title":"Mesenchymal stem cell-derived exosomes: applications in regenerative medicine","volume":"10","author":"Hade","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0305","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/cpt.3562","article-title":"Japan\u2019s conditional\/time-limited early approval system in regenerative medicine: a case study of rise and falls of autologous skeletal myoblast sheets","volume":"117","author":"Hakariya","year":"2025","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109133_bb0310","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/aor.14503","article-title":"FDA modernization Act 2.0 allows for alternatives to animal testing","volume":"47","author":"Han","year":"2023","journal-title":"Artificial Organs"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109133_bb0315","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow\u2013derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the Poseidon randomized trial","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2023.100614","article-title":"Injectable hydrogels in central nervous system: Unique and novel platforms for promoting extracellular matrix remodeling and tissue engineering","volume":"20","author":"Hasanzadeh","year":"2023","journal-title":"Materials Today. Bio"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1650885","article-title":"Stem cell therapy offers new hope for the treatment of Alzheimer\u2019s disease","volume":"13","author":"He","year":"2025","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0330","author":"Health Canada"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109133_bb0335","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.scr.2009.02.002","article-title":"Teratoma formation by human embryonic stem cells: Evaluation of essential parameters for future safety studies","volume":"2","author":"Hentze","year":"2009","journal-title":"Stem Cell Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2036","article-title":"Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review","volume":"7","author":"Hetta","year":"2024","journal-title":"Health Science Reports"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2023.101739","article-title":"Evaluation of next-generation sequencing performance for in vitro detection of viruses in biological products","volume":"85","author":"Hirai","year":"2024","journal-title":"Biologicals"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1375177","article-title":"Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation","volume":"15","author":"Ho","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0355","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41578-021-00279-y","article-title":"Engineering organoids","volume":"6","author":"Hofer","year":"2021","journal-title":"Nature Reviews Materials"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109133_bb0360","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.stemcr.2024.10.006","article-title":"Amendments to ASRM: Can we move away from a \u201cTherapeutic Haven\u201d?","volume":"19","author":"Ikka","year":"2024","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0365","author":"International Council for Harmonisation"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109133_bb0370","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.stem.2023.07.004","article-title":"Regulation of advanced therapies in Europe: Are we on the right track?","volume":"30","author":"Izeta","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0375","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/stem.1634","article-title":"Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial","volume":"32","author":"Jo","year":"2014","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0380","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1038\/s41598-020-60466-9","article-title":"Development of genetic quality tests for good manufacturing practice-compliant induced pluripotent stem cells and their derivatives","volume":"10","author":"Jo","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0385","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fimmu.2016.00470","article-title":"Milestones of hematopoietic stem cell transplantation\u2014from first human studies to current developments","volume":"7","author":"Juric","year":"2016","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109133_bb0390","doi-asserted-by":"crossref","first-page":"907.e1","DOI":"10.1016\/j.jtct.2024.06.023","article-title":"Real-world outcomes of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in Japan: retrospective analysis of the transplant registry unified management program registry","volume":"30","author":"Kanda","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0395","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.reth.2024.09.015","article-title":"Regulatory insights on advanced CAR-T cell products, AAV-based Gene therapies, and medical care\/practice in cell and Gene therapies: Report from the 6th Asia partnership conference of regenerative medicine- April 20, 2023","volume":"26","author":"Karasawa","year":"2024","journal-title":"Regenerative Therapy"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0400","series-title":"International Society for Cell & Gene Therapy (ISCT)","article-title":"FDA\u2019s approval of Ryoncil: A milestone for MSC therapy or just the beginning? [News Hub]","author":"Khan","year":"2025"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109133_bb0405","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s13770-025-00782-1","article-title":"Therapeutic efficacy of mesenchymal stem cells (MSCs) on Alzheimer\u2019s disease: review of clinical results","volume":"23","author":"Kim","year":"2026","journal-title":"Tissue Engineering and Regenerative Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109133_bb0410","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s13770-025-00742-9","article-title":"Establishment of immune-evasive iPSCs from PBMCs Using B2M Knockout and CD47\/HLA-E overexpression","volume":"22","author":"Kim","year":"2025","journal-title":"Tissue Engineering and Regenerative Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109133_bb0415","doi-asserted-by":"crossref","DOI":"10.1093\/stcltm\/szag048","article-title":"A Phase 1 clinical trial to evaluate the safety and tolerability of CLZ-2002 for the treatment of patients with Charcot\u2013Marie\u2013Tooth disease type 1","volume":"15","author":"Kim","year":"2026","journal-title":"Stem Cells Translational Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0420","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13195-021-00897-2","article-title":"Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer\u2019s disease dementia: A phase I clinical trial","volume":"13","author":"Kim","year":"2021","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0425","doi-asserted-by":"crossref","first-page":"45","DOI":"10.24304\/kjcp.2025.35.1.45","article-title":"Studies on the Comparison of the Expedited Programs for Regenerative Medicine Therapies among the United States, the European Union and the Republic of Korea","volume":"35","author":"Ko","year":"2025","journal-title":"Korean Journal of Clinical Pharmacy"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109133_bb0430","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41578-019-0129-9","article-title":"Engineered materials for organoid systems","volume":"4","author":"Kratochvil","year":"2019","journal-title":"Nature Reviews Materials"},{"issue":"28","key":"10.1016\/j.pharmthera.2026.109133_bb0435","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk9918","article-title":"Injectable shear-thinning hydrogels promote oligodendrocyte progenitor cell survival and remyelination in the central nervous system","volume":"10","author":"Kumar Podder","year":"2024","journal-title":"Science Advances"},{"issue":"7467","key":"10.1016\/j.pharmthera.2026.109133_bb0440","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature12517","article-title":"Cerebral organoids model human brain development and microcephaly","volume":"501","author":"Lancaster","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109133_bb0445","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","article-title":"Engineering universal cells that evade immune detection","volume":"19","author":"Lanza","year":"2019","journal-title":"Nature Reviews Immunology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109133_bb0450","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.3267","article-title":"Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies","volume":"19","author":"Lee","year":"2013","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0455","doi-asserted-by":"crossref","first-page":"272","DOI":"10.12779\/dnd.2025.24.4.272","article-title":"Mesenchymal stem cells with adjuvant dexamethasone in patients with Alzheimer\u2019s disease: A phase IIa trial","volume":"24","author":"Lee","year":"2025","journal-title":"Dementia and Neurocognitive Disorders"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0460","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13287-022-02751-0","article-title":"Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: A systematic review","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Research & Therapy"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109133_bb0465","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jcyt.2017.06.009","article-title":"A roadmap for cost-of-goods planning to guide economic production of cell therapy products","volume":"19","author":"Lipsitz","year":"2017","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109133_bb0470","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/er.2008-0031","article-title":"Ethical issues in stem cell research","volume":"30","author":"Lo","year":"2009","journal-title":"Endocrine Reviews"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0475","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41573-020-0079-3","article-title":"Organs-on-chips: Into the next decade","volume":"20","author":"Low","year":"2021","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0480","article-title":"Pluripotent stem cell-derived cell therapy for the treatment of type 1 diabetes","volume":"303\u2013310","author":"Ma","year":"2025","journal-title":"American Journal of Student Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109133_bb0485","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","article-title":"Autologous induced stem-cell\u2013derived retinal cells for macular degeneration","volume":"376","author":"Mandai","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0490","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.stem.2014.10.004","article-title":"Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR\/Cas9","volume":"15","author":"Mandal","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0495","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13036-019-0163-6","article-title":"Transplantation of CRISPRa system engineered IL10-overexpressing bone marrow-derived mesenchymal stem cells for the treatment of myocardial infarction in diabetic mice","volume":"13","author":"Meng","year":"2019","journal-title":"Journal of Biological Engineering"},{"issue":"7653","key":"10.1016\/j.pharmthera.2026.109133_bb0500","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature22312","article-title":"Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations","volume":"545","author":"Merkle","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101076","article-title":"Definitions, incidence and outcome of poor graft function after hematopoietic cell transplantation: A systematic review and meta-analysis","volume":"60","author":"M\u00fcskens","year":"2023","journal-title":"Blood Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0510","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/cddiscovery.2017.2","article-title":"Haematopoietic stem cells: Past, present and future","volume":"3","author":"Ng","year":"2017","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0515","article-title":"Announcement of obtaining a license for manufacturing regenerative medicine products by Nikon CeLL innovation Co., Ltd","author":"Nikon.","year":"2020","journal-title":"News | Nikon About Us"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109133_bb0520","article-title":"3D printing of personalized thick and perfusable cardiac patches and hearts","volume":"6","author":"Noor","year":"2019","journal-title":"Advanced Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109133_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.crmeth.2024.100779","article-title":"Bioengineering methods for vascularizing organoids","volume":"4","author":"Nwokoye","year":"2024","journal-title":"Cell Reports Methods"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109133_bb0530","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/stem.3058","article-title":"Application of tonsil-derived mesenchymal stem cells in tissue regeneration: concise review","volume":"37","author":"Oh","year":"2019","journal-title":"Stem Cells"},{"issue":"7151","key":"10.1016\/j.pharmthera.2026.109133_bb0535","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature05934","article-title":"Generation of germline-competent induced pluripotent stem cells","volume":"448","author":"Okita","year":"2007","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109133_bb0540","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.stem.2016.02.011","article-title":"Complex tissue and disease modeling using hiPSCs","volume":"18","author":"Passier","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0545","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplantation"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0550","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM200102013440516","article-title":"Repair of large bone defects with the use of autologous bone marrow stromal cells","volume":"344","author":"Quarto","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109133_bb0555","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ng.3487","article-title":"A predictive computational framework for direct reprogramming between human cell types","volume":"48","author":"Rackham","year":"2016","journal-title":"Nature Genetics"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109133_bb0560","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.stem.2021.10.003","article-title":"Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes","volume":"28","author":"Ramzy","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109133_bb0565","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMoa2506549","article-title":"Stem cell\u2013derived, fully differentiated islets for type 1 diabetes","volume":"393","author":"Reichman","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0570","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood-2010-09-306829","article-title":"HLA-matched sibling bone marrow transplantation for \u03b2-thalassemia major","volume":"117","author":"Sabloff","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109133_bb0575","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/thoraxjnl-2013-204110","article-title":"Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma","volume":"69","author":"Sage","year":"2014","journal-title":"Thorax"},{"issue":"7244","key":"10.1016\/j.pharmthera.2026.109133_bb0580","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"issue":"9967","key":"10.1016\/j.pharmthera.2026.109133_bb0590","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","article-title":"Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: Follow-up of two open-label phase 1\/2 studies","volume":"385","author":"Schwartz","year":"2015","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109133_bb0595","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s13770-024-00672-y","article-title":"Potential use of organoids in regenerative medicine","volume":"21","author":"Septiana","year":"2024","journal-title":"Tissue Engineering and Regenerative Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109133_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100466","article-title":"Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device","volume":"2","author":"Shapiro","year":"2021","journal-title":"Cell Reports Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109133_bb0605","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: A decade of progress","volume":"16","author":"Shi","year":"2017","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0610","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s13770-025-00760-7","article-title":"A 3D printed Poly(\u03b5-caprolactone)-collagen hybrid mesh (TissueDerm) for breast reconstruction after mastectomy in a pig model","volume":"23","author":"Shim","year":"2026","journal-title":"Tissue Engineering and Regenerative Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0615","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41551-022-00987-y","article-title":"Challenges in the clinical advancement of cell therapies for Parkinson\u2019s disease","volume":"7","author":"Skidmore","year":"2023","journal-title":"Nature Biomedical Engineering"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0585","author":"Standards Coordinating Body (SCB)"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0620","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fcell.2020.00068","article-title":"Primary Mammary Organoid Model of Lactation and Involution","volume":"8","author":"Sumbal","year":"2020","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0625","series-title":"Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product \u201cAMCHEPRY\u201d in Japan","author":"Sumitomo Pharma","year":"2026"},{"issue":"8064","key":"10.1016\/j.pharmthera.2026.109133_bb0630","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41586-025-08845-y","article-title":"Phase I trial of hES cell-derived dopaminergic neurons for Parkinson\u2019s disease","volume":"641","author":"Tabar","year":"2025","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109133_bb0635","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nrg3563","article-title":"Pluripotent stem cells in regenerative medicine: Challenges and recent progress","volume":"15","author":"Tabar","year":"2014","journal-title":"Nature Reviews Genetics"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109133_bb0640","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.oret.2019.04.021","article-title":"Evaluation of transplanted autologous induced pluripotent stem cell-derived retinal pigment epithelium in exudative age-related macular degeneration","volume":"3","author":"Takagi","year":"2019","journal-title":"Ophthalmology Retina"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0645","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.reth.2020.06.002","article-title":"iPS cell-based therapy for Parkinson\u2019s disease: A Kyoto trial","volume":"13","author":"Takahashi","year":"2020","journal-title":"Regenerative Therapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0650","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0655","author":"Telegraft Hub"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acschemneuro.3c00531","article-title":"Aging hallmarks and progression and age-related diseases: A landscape view of research advancement","volume":"15","author":"Tenchov","year":"2024","journal-title":"ACS Chemical Neuroscience"},{"issue":"5391","key":"10.1016\/j.pharmthera.2026.109133_bb0665","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","article-title":"Embryonic stem cell lines derived from human blastocysts","volume":"282","author":"Thomson","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1366297","article-title":"Relative efficacy and safety of mesenchymal stem cells for osteoarthritis: A systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Tian","year":"2024","journal-title":"Frontiers in Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109133_bb0675","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2307\/3570892","article-title":"A direct measurement of the radiation sensitivity of normal mouse bone marrow cells","volume":"14","author":"Till","year":"1961","journal-title":"Radiation Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0680","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2015.06.007","article-title":"Stem cell therapies in clinical trials: Progress and challenges","volume":"17","author":"Trounson","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109133_bb0685","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41591-024-03489-3","article-title":"Clinical applications of human organoids","volume":"31","author":"Verstegen","year":"2025","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109133_bb0690","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","article-title":"Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT\u00ae) Mesenchymal Stromal Cell committee position statement on nomenclature","volume":"21","author":"Viswanathan","year":"2019","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109133_bb0695","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3727\/000000004783983747","article-title":"Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: Two case reports","volume":"13","author":"Wakitani","year":"2004","journal-title":"Cell Transplantation"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0700","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109133_bb0705","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.stem.2020.09.014","article-title":"Pluripotent stem cell-based cell therapy\u2014promise and challenges","volume":"27","author":"Yamanaka","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109133_bb0710","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.stem.2023.12.009","article-title":"3D bioprinting of human neural tissues with functional connectivity","volume":"31","author":"Yan","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.pharmthera.2026.109133_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbon.2024.118970","article-title":"Hydrogel-integrated graphene superstructures for tissue engineering: From periodontal to neural regeneration","volume":"223","author":"Zare","year":"2024","journal-title":"Carbon"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109133_bb0720","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s43586-022-00174-y","article-title":"Organoids","volume":"2","author":"Zhao","year":"2022","journal-title":"Nature Reviews Methods Primers"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:58:46Z","timestamp":1793977126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":144,"alternative-id":["S0163725826001609"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109133","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating the landscape of stem cell therapeutics: Overcoming translational hurdles via emerging technologies and regulatory frontiers","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109133"}}